Top Image: Cytospin smear from a patient with myelodysplasia with megakaryocytic with 3 separate nuclei (so-called "pawn ball" megakaryocyte).

Get the Flash Player to see this rotator.


This portal is a resource for myelodysplastic syndrome (MDS) diagnosis, classification and treatment for Pathologists, Hematopathologists, Oncologists, Hematologists and other Clinical Professionals.

The overall incidence rate for myelodysplastic syndrome (MDS) is 4.4 cases per 100,000.1 Between 2004 and 2008 there were over 62,886 new cases of MDS throughout the United States, averaging an estimated 12,577 cases per year.2 Evidence suggests that the incidence of MDS may in fact be even higher due to underreporting of MDS to centralized cancer registries.3

Since treatment recommendations vary by IPSS risk group, accurate diagnosis and classification is critical. The complexity of the diagnosis in MDS underscores the need to educate general pathologists and hematopathologists about accurate diagnosis, application of appropriate prognostic tools, and the use of standardized terminology for effective and clear communications with the treating hematologist/oncologist for determining the best therapeutic plan for treatment of patients with MDS.

To address the educational gaps in the diagnosis of MDS, the American Society for Clinical Pathology (ASCP) has designed a comprehensive MDS-directed educational curriculum titled, The Diagnosis, Classification and Clinical Care of MDS (DC3-MDS). This DC3-MDS website is uniquely designed to facilitate access to education and resources.

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

1SEER (Surveillance, Epidemiology and End Results). Cancer Statistics Review, 1975-2008. National Cancer Institute; 2011.
2Leukemia & Lymphoma Society. Facts 2012. Available at: Accessed March 2013.
3Cogle CR, Craig BM, Rollison DE, List AF. Incidence of myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121-7135.